Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 2/20 | 0.34 |
| ▸ | TYK2 | P29597 | 1/20 | 0.31 |
| ▸ | JAK3 | P52333 | 1/20 | 0.31 |
| ▸ | CTSL | P07711 | 1/20 | 0.31 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21159102 | 0.92 | RET (0.33) | RETTYK2JAK3 | |
| SCHEMBL23555165 | 0.82 | RET (0.38) | RETTYK2JAK3CTSLGPR119 | |
| SCHEMBL20153224 | 0.80 | RET (0.37) | RETTYK2JAK3CTSLGPR119 | |
| SCHEMBL20154607 | 0.78 | RET (0.40) | RETTYK2JAK3GPR119 | |
| SCHEMBL23126245 | 0.77 | RET (0.36) | RETTYK2JAK3CTSLGPR119 | |
| SCHEMBL24785486 | 0.77 | HTR3A (0.34) | RETTYK2JAK3CTSLGPR119 | |
| SCHEMBL13034559 | 0.74 | JAK3 (0.38) | RETTYK2JAK3CTSLGPR119 | |
| SCHEMBL20153223 | 0.73 | RET (0.36) | RETTYK2JAK3GPR119 | |
| SCHEMBL12988305 | 0.71 | JAK3 (0.35) | RETTYK2JAK3CTSLGPR119 | |
| SCHEMBL20148740 | 0.70 | HRH3 (0.41) | RETTYK2JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190183886-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2019-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190183886-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, ROR1, BRAF | RET 1/4885TYK2 217/4885JAK3 45/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.